Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Successfully transitioned into a fully integrated commercial-stage company following the first two independent launches of TRYNGOLZA and DAWNZERA. Performance attribution for TRYNGOLZA was driven by a compelling clinical profile and strong execution, exceeding expectations with $108 million in full-year revenue. Achieved breakthrough Phase III results for olezarsen in severe hypertriglyceridemia, demonstrating an unprecedented 85% reduction in acute pancreatitis events. Strategic positioning in neurology was bolstered by positive Phase III data for zilganersen, the first therapy to show disease-modifying benefits in Alexander disease. Revenue growth of 34% year-over-year was supported by a diversified model where marketed medicines provide recurring income while R&D collaborations act as financial accelerators. Maintained disciplined investment strategies, enab
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual MeetingBusiness Wire
- Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.MarketBeat
- Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)Business Wire
- Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 2/26/26 - Form 10-K
- 2/25/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- IONS's page on the SEC website